Get access

New pathogenic paradigms in inflammatory bowel disease

Authors

  • Antonio Di Sabatino MD,

    Corresponding author
    1. First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche Intestinali, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy
    • Clinica Medica I, Fondazione IRCCS Policlinico S. Matteo, Piazzale Golgi 5, 27100 Pavia, Italy
    Search for more papers by this author
  • Paolo Biancheri MD,

    1. Centre for Immunology and Infectious Disease, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
    Search for more papers by this author
  • Laura Rovedatti MD,

    1. First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche Intestinali, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy
    Search for more papers by this author
  • Thomas T. MacDonald PhD, FRCPath, FMedSci,

    1. Centre for Immunology and Infectious Disease, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
    Search for more papers by this author
  • Gino R. Corazza MD

    1. First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche Intestinali, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy
    Search for more papers by this author

Abstract

Abstract: Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer “static” but “dynamic” vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease. (Inflamm Bowel Dis 2011;)

Ancillary